Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Sep;6(9):1481-7.
doi: 10.1097/JTO.0b013e31822918bd.

Development and validation of a quantitative real-time polymerase chain reaction classifier for lung cancer prognosis

Guoan Chen  1 , Sinae Kim, Jeremy M G Taylor, Zhuwen Wang, Oliver Lee, Nithya Ramnath, Rishindra M Reddy, Jules Lin, Andrew C Chang, Mark B Orringer, David G Beer
Affiliations
Randomized Controlled Trial

Development and validation of a quantitative real-time polymerase chain reaction classifier for lung cancer prognosis

Guoan Chen et al. J Thorac Oncol. 2011 Sep.

Abstract

Introduction: This prospective study aimed to develop a robust and clinically applicable method to identify patients with high-risk early-stage lung cancer and then to validate this method for use in future translational studies.

Methods: Three published Affymetrix microarray data sets representing 680 primary tumors were used in the survival-related gene selection procedure using clustering, Cox model, and random survival forest analysis. A final set of 91 genes was selected and tested as a predictor of survival using a quantitative real-time polymerase chain reaction-based assay using an independent cohort of 101 lung adenocarcinomas.

Results: The random survival forest model built from 91 genes in the training set predicted patient survival in an independent cohort of 101 lung adenocarcinomas, with a prediction error rate of 26.6%. The mortality risk index was significantly related to survival (Cox model p < 0.00001) and separated all patients into low-, medium-, and high-risk groups (hazard ratio = 1.00, 2.82, 4.42). The mortality risk index was also related to survival in stage 1 patients (Cox model p = 0.001), separating patients into low-, medium-, and high-risk groups (hazard ratio = 1.00, 3.29, 3.77).

Conclusions: The development and validation of this robust quantitative real-time polymerase chain reaction platform allows prediction of patient survival with early-stage lung cancer. Utilization will now allow investigators to evaluate it prospectively by incorporation into new clinical trials with the goal of personalized treatment of patients with lung cancer and improving patient survival.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Strategy for the development and validation of the 91-gene qRT-PCR classifier for lung cancer prognosis.
FIGURE 2
FIGURE 2
Prediction results of the 91-gene qRT-PCR signature in the 101 samples of validation set. A, Kaplan-Meier survival curve using patient mortality risk index (MRI) from the RSF prediction model built from training set including 91 genes, stage and age. This predictor could significantly separate high, medium and low-risk groups (1/3rd in each group, HR = 1.00, 2.82, 4.42, p = 0.0008) among all 101 patients (A), as well as among the 59 stage 1 patient (1/3rd in each group, HR = 1.00, 3.29, 3.776) (B).
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. - PubMed
    1. Strauss GM, Herndon JE, 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008;26:5043–5051. - PMC - PubMed
    1. Bezjak A, Lee CW, Ding K, et al. Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. J Clin Oncol. 2008;26:5052–5059. - PMC - PubMed
    1. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7:719–727. - PubMed
    1. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351–360. - PubMed

Publication types

MeSH terms